Power3 Medical Products, Inc. (PWRM.OB)

PWRM has filed several patent applications for its NuroPro technology that are currently pending. PWRM also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, PWRM has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. PWRM intends to publish these latest findings as well.

PWRM, a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. PWRM’s products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease. PWRM’s products analyze proteins and their mutations to assess an individual’s risk for developing disease later in life or a patient’s likelihood of responding to a particular drug; assess a patient’s risk of disease progression and disease recurrence; and measure a patient’s exposure to drug therapy. PWRM was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. PWRM was founded in 1992 and is based in The Woodlands, Texas.

PWRM continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS (Lou Gehrig’s disease), Alzheimer’s, Parkinson’s diseases, breast cancer, and drug resistance.

The NuroPro Blood Test is PWRM’s diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer’s disease, ALS (Lou Gehrig’s disease), and Parkinson’s disease.

PWRM’s BC-SeraPro(TM) is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient’s serum sample is compared to PWRM’s patient database. Statistical analysis by linear discriminant function will analyze the biomarker levels of the patient sample and assign a probability score for the diagnosis. Probability score is ranged from 0.0 to 1.0. Results of PWRM’s BC-SeraPro(TM) test should not be considered a stand alone diagnosis nor a guarantee and is intended to be used in conjunction with mammography and other accepted modalities.

PWRM expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer’s disease (NuroPro-AD), Parkinson’s disease (NuroPro-PD) and breast cancer in 2010, followed by filings with the FDA.

To learn more about PWRM visit: http://www.Power3Medical.com

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

The Board of Directors of The Interpublic Group of Companies, Inc. (NYSE:IPG) has declared a dividend of $13.125 per share on its 5¼% Series B Cumulative Convertible Perpetual Preferred Stock.

The dividend on the Series B Preferred Stock is payable in cash on October 15, 2010 to holders of record at the close of business on October 1, 2010. There will be a maximum of 221,474 shares of the Series B Preferred Stock outstanding on October 1, 2010, resulting in a maximum possible aggregate dividend of approximately $2,906,846.

The Interpublic Group of Companies, Inc., through its subsidiaries, provides advertising and marketing services worldwide. It delivers various services across marketing disciplines and specialties, including advertising, direct marketing, media buying and planning, public relations, events marketing, Internet and search engine marketing, social media marketing, and mobile marketing.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Intersil Corporation (NASDAQ:ISIL) will announce its third quarter 2010 financial results on Wednesday, October 20, 2010 at 1:45 pm Pacific Time.

Dave Bell, Intersil's President and Chief Executive Officer, and Jonathan Kennedy, Senior Vice President and Chief Financial Officer, will provide details on the company's financial performance and an outlook for the fourth quarter of 2010.

Intersil Corporation engages in the design, manufacture, and marketing of analog integrated circuits (ICs). The company offers a range of application specific standard products and general purpose proprietary products for consumer, industrial, computing, and communications markets. Its high-end consumer products include gaming, light sensors, optical storage, displays, and handheld products, which are used in electronic game systems, DVD players and recorders, MP3 players, GPS systems, liquid crystal display televisions, data converters, and smart cell phones.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Interval International, a prominent worldwide provider of vacation services and an operating segment of Interval Leisure Group (Nasdaq:IILG), has added The Reef Playacar Resort and Spa, in the heart of Mexico’s Riviera Maya, to its quality exchange network.

Situated in the town of Playa del Carmen, the beachfront property features 202 suites surrounded by lush tropical gardens.

Interval Leisure Group, Inc., together with its subsidiaries, provides membership and leisure services to the vacation industry worldwide. The company operates through two segments, Interval and Aston.

*************************************************************

For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup

*************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (PWRM.OB)